Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 135,543,488
  • Shares Outstanding, K 729,670
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.35
  • Price/Sales 5.92
  • Price/Cash Flow 12.75
  • Price/Book 4.29

Price Performance

See More
Period Period Low Period High Performance
1-Month
168.57 +10.20%
on 08/24/17
191.10 -2.79%
on 09/14/17
+15.69 (+9.23%)
since 08/22/17
3-Month
166.52 +11.55%
on 08/18/17
191.10 -2.79%
on 09/14/17
+11.94 (+6.87%)
since 06/22/17
52-Week
133.64 +39.00%
on 11/04/16
191.10 -2.79%
on 09/14/17
+10.14 (+5.77%)
since 09/22/16

Most Recent Stories

More News
Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts

Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional...

AMGN : 185.76 (-0.47%)
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

URGN : 30.49 (+3.32%)
ABEO : 14.95 (-7.72%)
CLSD : 8.30 (+1.84%)
RETA : 31.75 (+0.41%)
NVS : 86.16 (+1.44%)
GILD : 83.27 (+0.79%)
RHHBY : 32.0200 (-0.06%)
KITE : 179.30 (-0.04%)
AMGN : 185.76 (-0.47%)
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
AMGN : 185.76 (-0.47%)
PFE : 35.96 (-0.03%)
AMGEN (AMGN) ALERT: Johnson Fistel Announces Investigation of Amgen Inc.; Investors that Bought Before March 17, 2017, Encouraged to Contact the Firm

Johnson Fistel, LLP, a shareholder rights law firm, is investigating potential claims on behalf of investors of Amgen Inc. (NASDAQ: AMGN) ("Amgen"). Amgen discovers, develops, manufactures, and delivers...

AMGN : 185.76 (-0.47%)
Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel

Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the appointment of Alex Driggs to General Counsel and Corporate Secretary. Mr. Driggs joined Sucampo...

SCMP : 11.80 (-0.42%)
AMGN : 185.76 (-0.47%)
Novartis Poised to Grow on Oncology Portfolio & Biosimilars

Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ALXN : 142.82 (-0.07%)
deCODE Study Reveals an Ancient Achilles Heel in the Human Genome

REYKJAVIK, Iceland, September 20, 2017 /PRNewswire/ --

AMGN : 185.76 (-0.47%)
deCODE Study Reveals an Ancient Achilles Heel in the Human Genome

-- The generation of new mutations is a key driver of evolution but also of susceptibility to rare diseases

AMGN : 185.76 (-0.47%)
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

VRTX : 151.26 (-0.53%)
BMRN : 94.95 (+1.64%)
ABBV : 87.48 (+0.08%)
TSRO : 119.04 (+0.31%)
NBRV : 8.47 (+1.44%)
AMGN : 185.76 (-0.47%)
HALO : 16.78 (+1.08%)
Is Amgen (AMGN) a Great Stock for Value Investors?

Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

AMGN : 185.76 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 188.35
1st Resistance Point 187.05
Last Price 185.76
1st Support Level 184.23
2nd Support Level 182.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.